SNDX-5613 [2169919-21-3]
Cat# NB-64-04475-1mL
Size : 1mLx10mM(inDMSO)
Brand : Neo Biotech
Contact local distributor :
Phone : +1 850 650 7790
SNDX-5613
Catalog No. T12943 Copy Product Info
Purity: 99.97%
Revumenib (SNDX-5613) is a potent and selective oral inhibitor of menin-KMT2A interaction with Ki of 0.149 nM and IC50 between 10 and 20 nM, which can be used in the study of acute leukemia with MLL gene rearrangement.
SNDX-5613
Copy Product InfoRevumenib (SNDX-5613) is a potent and selective oral inhibitor of menin-KMT2A interaction with Ki of 0.149 nM and IC50 between 10 and 20 nM, which can be used in the study of acute leukemia with MLL gene rearrangement.
Cas No. 2169919-21-3
Customer service consultation
Select Batch
Purity:99.97%
Appearance:Solid
Color:White to Yellow
Contact us for more batch information
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | Revumenib (SNDX-5613) is a potent and selective oral inhibitor of menin-KMT2A interaction with Ki of 0.149 nM and IC50 between 10 and 20 nM, which can be used in the study of acute leukemia with MLL gene rearrangement. |
| Targets&IC50 | Menin-MLL:10-20 nM |
| In vitro | METHODS: Primary patient-derived NUP98-r AML cells were treated with Revumenib (SNDX-5613) (2, 46, 125 nM) and cell viability was measured. RESULTS Revumenib inhibited the growth of primary patient-derived NUP98-r AML cells. [3] |
| In vivo | SNDX-5613 treatment provides significant survival benefit and leukemic control in aggressive MOLM-13 disseminated xenografts.SNDX-5613 shows in vivo plasma( IC50 : 53 nM) . |
| Molecular Weight | 630.82 |
| Formula | C32H47FN6O4S |
| Cas No. | 2169919-21-3 |
| Smiles | CCN(C(C)C)C(=O)c1cc(F)ccc1Oc1cncnc1N1CC2(C1)CCN(C[C@H]1CC[C@@H](CC1)NS(=O)(=O)CC)CC2 |
| Relative Density. | 1.28 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 52 mg/mL (82.43 mM), Sonication is recommended.  | ||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween-80+45% Saline: 4 mg/mL (6.34 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | |||||||||||||||||||||||||||||||
You might also be interested by the following products:
Cat#
Description
Cond.
Price Bef. VAT